Holly Steininger

Holly Steininger

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2021 in Nature
Verified
Journal Article
Closed access
PDF file
TAThomas H. Ambrosi
Thomas H. Ambrosi
OMOwen Marecic
Owen Marecic
AMAdrian McArdle
Adrian McArdle
RSRahul Sinha
Rahul Sinha
GGGunsagar S. Gulati
Gunsagar S. Gulati
CCCharles KF Chan
Charles KF Chan

17 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MMMatthew P. Murphy
Matthew P. Murphy
LKLauren S. Koepke
Lauren S. Koepke
MLMichael T. Lopez
Michael T. Lopez
XTXinming Tong
Xinming Tong
TAThomas H. Ambrosi
Thomas H. Ambrosi
CCCharles KF Chan
Charles KF Chan

30 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TATom W. Andrew
Tom W. Andrew
LKLauren S. Koepke
Lauren S. Koepke
YWYuting Wang
Yuting Wang
MLMichael Lopez
Michael Lopez
HSHolly Steininger
Holly Steininger
CCCharles KF Chan
Charles KF Chan
Sexually dimorphic tissues are formed by cells that are regulated by sex hormones. While a number of systemic hormones and transcription factors are known to regulate proliferation and differentiation of osteoblasts and osteoclasts, the mechanisms that determine sexually dimorphic differences in bone regeneration are unclear. To explore how sex hormones regulate bone regeneration, we compared bone fracture repair between adult male and female mice. We found that skeletal stem cell (SSC) mediated regeneration in female mice is dependent on estrogen signaling but SSCs from male mice do not exhibit similar estrogen responsiveness. Mechanistically, we found that estrogen acts directly on the SSC lineage in mice and humans by up-regulating multiple skeletogenic pathways and is necessary for the stem cell’s ability to self- renew and differentiate. Our results also suggest a clinically applicable strategy to accelerate bone healing using localized estrogen hormone therapy.

14 June 2023 in Nature Protocols
Verified
Journal Article
Open access
PDF file
MHMalachia Y. Hoover
Malachia Y. Hoover
TAThomas H. Ambrosi
Thomas H. Ambrosi
HSHolly Steininger
Holly Steininger
LKLauren S. Koepke
Lauren S. Koepke
YWYuting Wang
Yuting Wang
CCCharles KF Chan
Charles KF Chan
Human skeletal stem cells (hSSCs) hold tremendous therapeutic potential for developing new clinical strategies to effectively combat congenital and age-related musculoskeletal disorders. Unfortunately, refined methodologies for the proper isolation of bona fide hSSCs and the development of functional assays that accurately recapitulate their physiology within the skeleton have been lacking. Bone marrow-derived mesenchymal stromal cells (BMSCs), commonly used to describe the source of precursors for osteoblasts, chondrocytes, adipocytes and stroma, have held great promise as the basis of various approaches for cell therapy. However, the reproducibility and clinical efficacy of these attempts have been obscured by the heterogeneous nature of BMSCs due to their isolation by plastic adherence techniques. To address these limitations, our group has refined the purity of individual progenitor populations that are encompassed by BMSCs by identifying defined populations of bona fide hSSCs and their downstream progenitors that strictly give rise to skeletally restricted cell lineages. Here, we describe an advanced flow cytometric approach that utilizes an extensive panel of eight cell surface markers to define hSSCs; bone, cartilage and stromal progenitors; and more differentiated unipotent subtypes, including an osteogenic subset and three chondroprogenitors. We provide detailed instructions for the FACS-based isolation of hSSCs from various tissue sources, in vitro and in vivo skeletogenic functional assays, human xenograft mouse models and single-cell RNA sequencing analysis. This application of hSSC isolation can be performed by any researcher with basic skills in biology and flow cytometry within 1–2 days. The downstream functional assays can be performed within a range of 1–2 months.

3 May 2023 in Gels
Verified
Journal Article
Open access
PDF file
ETEri Takematsu
Eri Takematsu
MMMatthew Philip Murphy
Matthew Philip Murphy
SHSophia Hou
Sophia Hou
HSHolly Steininger
Holly Steininger
AAAlina Alam
Alina Alam
CCCharles KF Chan
Charles KF Chan
Bone- and cartilage-related diseases, such as osteoporosis and osteoarthritis, affect millions of people worldwide, impairing their quality of life and increasing mortality. Osteoporosis significantly increases the bone fracture risk of the spine, hip, and wrist. For successful fracture treatment and to facilitate proper healing in the most complicated cases, one of the most promising methods is to deliver a therapeutic protein to accelerate bone regeneration. Similarly, in the setting of osteoarthritis, where degraded cartilage does not regenerate, therapeutic proteins hold great promise to promote new cartilage formation. For both osteoporosis and osteoarthritis treatments, targeted delivery of therapeutic growth factors, with the aid of hydrogels, to bone and cartilage is a key to advance the field of regenerative medicine. In this review article, we propose five important aspects of therapeutic growth factor delivery for bone and cartilage regeneration: (1) protection of protein growth factors from physical and enzymatic degradation, (2) targeted growth factor delivery, (3) controlling GF release kinetics, (4) long-term stability of regenerated tissues, and (5) osteoimmunomodulatory effects of therapeutic growth factors and carriers/scaffolds.

25 August 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
LGL. Henry Goodnough
L. Henry Goodnough
TAThomas H. Ambrosi
Thomas H. Ambrosi
HSHolly Steininger
Holly Steininger
MBM. Gohazrua K. Butler
M. Gohazrua K. Butler
MHMalachia Y. Hoover
Malachia Y. Hoover
CCCharles KF Chan
Charles KF Chan
Fracture healing is highly dependent on an early inflammatory response in which prostaglandin production by cyclo-oxygenases (COX) plays a crucial role. Current patient analgesia regimens favor opioids over Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) since the latter have been implicated in delayed fracture healing. While animal studies broadly support a deleterious role of NSAID treatment to bone-regenerative processes, data for human fracture healing remains contradictory. In this study, we prospectively isolated mouse and human skeletal stem cells (SSCs) from fractures and compared the effect of various NSAIDs on their function. We found that osteochondrogenic differentiation of COX2-expressing mouse SSCs was impaired by NSAID treatment. In contrast, human SSCs (hSSC) downregulated COX2 expression during differentiation and showed impaired osteogenic capacity if COX2 was lentivirally overexpressed. Accordingly, short- and long-term treatment of hSSCs with non-selective and selective COX2 inhibitors did not affect colony forming ability, chondrogenic, and osteogenic differentiation potential in vitro. When hSSCs were transplanted ectopically into NSG mice treated with Indomethacin, graft mineralization was unaltered compared to vehicle injected mice. Thus, our results might contribute to understanding species-specific differences in NSAID sensitivity during fracture healing and support emerging clinical data which conflicts with other earlier observations that NSAID administration for post-operative analgesia for treatment of bone fractures are unsafe for patients.